Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia

Abstract

Project management, coordination, formal analysis, data preservation, first draft, revision and editing of the manuscript, methodology and research. Pilar Navajas Hernández: Data collection and preservation, revision and editing of the manuscript. María del Mar Martín Rodríguez: Data collection and preservation, revision and editing of the manuscript. Marta Lázaro Sáez: Data collection and preservation, formal analysis, first draft, revision and editing of the manuscript. Raúl Olmedo Martín: Data collection and preservation, revision and editing of the manuscript. Andrea Núñez Ortiz: Data collection and preservation, revision and editing of the manuscript. Federico Arguelles Arias: Data collection and preservation, revision and editing of the manuscript. María Carmen Fernández Cano: Data collection and preservation, revision and editing of the manuscript. Francisco Gallardo Sánchez: Data collection and preservation, revision and editing of the manuscript. Sandra Marín Pedrosa: Data collection and preservation, revision and editing of the manuscript.Javier González García: Data collection and preservation, revision and editing of the manuscript.Juan María Vázquez Morón: Project management, coordination, methodology, data collection and preservation, revision and editing of the manuscript. Conflicts of interest:A. Hernández has received payments as fees-for-service, participation in scientific meetings and funding for attendance from Abbvie, Ferring, Janssen, MSD, Pfizer, Sandoz and Takeda; M.M. Martín has received payments for advisory, participation in scientific meetings and attendance from MSD, Takeda, Janssen, Abbvie, Tillots Pharma, Chiesi and Ferring; M. Lázaro has received payments as fees-for-service, participation in scientific meetings and funding for attendance from Janssen, Pfizer and Takeda; R.Olmedo has received payments as fees-for-service and advisory from MSD, Abbvie, Takeda, Ferring, FAES Farma and Janssen; F. Arguelles has received payments for advisory, consultancy and research fundings from Janssen, MSD, Abbvie,

Clinical settings with tofacitinib in ulcerative colitis

“…A single study compared steroid-free remission rates and observed no significant differences between patients exposed to biologics (48%) and unexposed patients (55%). A more recent study, in which 98.3% of patients had been exposed to biologics, confirms the efficacy of tofacitinib in a highly refractory population (37).…”

Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study

“…Previous studies also showed similar trends for biochemical improvements after tofacitinib treatment. 13 , 16 – 18 , 20 , 21 , 28 Previous studies have also shown that higher serum CRP and lower serum albumin levels are correlated with severe clinical and endoscopic disease activities and poor prognosis. 38 – 41 In addition, improvement in the serum CRP and albumin within a short period after starting the biologic treatment has been reported to be related with better outcomes for UC patients.…”

“…These results are similar to those of other real-world studies, which reported 0–1.3% of patients developing venous thromboembolism after tofacitinib therapy. 14 , 16 – 22 , 24 , 27 …”

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

“…Up to now, in only one relatively small, retrospective cohort remission rates of tofacitinib in UC patients after 24 months of treatment were described. 16 In 13 patients, 53.8% were in remission after 24 months (defined as a partial Mayo score ≤2), but it was unclear whether an intention to treat analysis was used. Other studies evaluated the effectiveness of tofacitinib up to 1 year of treatment.…”